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Dear Editor, 
Dapsone is a dual-function drug with antimicro-
bial and antiprotozoal effects and anti-inflammatory 
features (1). In dermatology, it is a first choice for con-
ditions such as leprosy, IgA pemphigus, dermatitis 
herpetiformis, and linear IgA bullous dermatosis, or 
an adjunctive treatment for, e.g. bullous pemphigoid 
(BP) and pemphigus vulgaris (1). However, dapsone is 
associated with some adverse effects, including met-
hemoglobinemia (1). 
Methemoglobin (MetHb) concentrations of less 
than 15% usually cause no symptoms in patients with 
normal hemoglobin concentrations (2). Herein, we 
report the case of a patient with BP who developed 
dyspnea because of dapsone-induced methemoglo-
binemia that was as mild as 4.7%.
A 93-year-old man was diagnosed with BP based 
on skin manifestations (Figure 1, a and b), histopath-
ological findings (Figure 1, c and d), and anti-BP180 
NC16A antibody titer determined by chemilumi-
nescence enzyme immunoassay (279 U/mL) 3 years 
earlier. His comorbidities included diabetes mellitus, 
chronic heart failure, right pleural effusion, and brain 
infarction. The patient had been successfully treated 
with oral prednisolone, so the steroid was tapered to 
4 mg/day. The blisters recurred, however, and new 
ones kept developing even though the prednisolone 
was increased to 25 mg/day. Dapsone (75 mg/day) 
was begun as adjunctive treatment, and new blister 
formation ceased. At one week from dapsone initia-
tion, the patient developed dyspnea, and his oxygen 
saturation as measured by pulse oximetry decreased 
to 88% on room air.
At presentation, his blood pressure was 118/78 
mmHg, the heart rate was 95 beats/minute, and 
axillary temperature was 36.3 °C. Neurological ex-
amination and consciousness findings remained 
unchanged compared with findings before dyspnea 
onset. Chest examination showed normal breath and 
heart sounds, but lip and peripheral cyanosis was 
present. Blood tests revealed a white blood cell count 
Figure 1. (a, b) Skin manifestations with tense blisters and erythema on the trunk and limbs. (c, d) Histopathological exami-
nation of the skin on the left thigh revealed subepidermal blistering with eosinophil infiltration (hematoxylin and eosin, ×20 
and ×200, respectively). (e) Clinical course.
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of 12,920/μl; red blood cells, 370×104/μl; hemoglobin, 
11.7 g/dl; and CMV antigenemia (or C7-HRP), nega-
tive. Chest CT and echocardiography indicated no re-
markable change compared with imaging from one 
year earlier. Arterial blood gas analysis showed a pH 
of 7.454, PaO2 63.1 mmHg, PaCO2 35.4 mmHg, HCO3
- 
24.3 mmol/L, SaO2 92.4%, and MetHb of 4.7%. These 
findings indicated a saturation gap (difference be-
tween SpO2 and SaO2) induced by MetHb. Upon ces-
sation of dapsone, MetHb levels and SpO2 returned 
to normal and the dyspnea resolved, implicating dap-
sone in the methemoglobinemia (Figure 1, e).
Differential diagnoses were pulmonary disease, 
heart disease, neuromuscular disease, sepsis, and 
drug intoxication. These possibilities were ruled out 
by the physical examination, drug history, vital signs, 
blood tests, and chest CT and echocardiography. 
In normal individuals, MetHb levels are less than 
1% (2). Healthy patients with normal hemoglobin 
concentrations develop cyanosis at MetHb level of 
15-20%, dyspnea at 20-50%, and coma at 50-70%, 
and die at more than 70% (2). However, patients with 
hematologic disease, acidosis, or cardiopulmonary 
diseases, for example, present with symptoms even 
with MetHb levels less than 15% (2,3). We inferred 
that our patient presented with dyspnea even under 
mild methemoglobinemia because he had anemia, 
chronic heart failure, and right pleural effusion.
The occurrence of dapsone-induced methemo-
globinemia with obvious symptoms is rare (1,4). Cli-
nicians should be aware that methemoglobinemia 
symptoms are influenced not only by MetHb concen-
trations but also by comorbidities.
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